Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
N Engl J Med
    April 2023
  1. VAN DYCK CH, Sabbagh M, Cohen S
    Lecanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2023;388:1631-1632.
    >> Share

  2. BRENMAN JE
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1631.
    >> Share

  3. POMARA N, Imbimbo BP
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630-1631.
    >> Share

  4. VALENZUELA MJ, Pascual-Leone A
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    >> Share

  5. ZENG BS, Tseng PT, Liang CS
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    >> Share

    January 2023
  6. GANDY S, Ehrlich ME
    Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.
    N Engl J Med. 2023;388:80-81.
    >> Share

  7. SABBAGH M, van Dyck CH
    Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.
    N Engl J Med. 2023 Jan 4:10.1056/NEJMc2215907#sa1. doi: 10.1056/NEJMc2215907.
    >> Share

    November 2022
  8. VAN DYCK CH, Swanson CJ, Aisen P, Bateman RJ, et al
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2022 Nov 29. doi: 10.1056/NEJMoa2212948.
    >> Share

    November 2021
  9. SACHS RE, Bagley N
    Medicare Coverage of Aducanumab - Implications for State Budgets.
    N Engl J Med. 2021;385:2019-2021.
    >> Share

  10. ROBINSON JC
    Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
    N Engl J Med. 2021;385:2017-2019.
    >> Share

    August 2021
  11. ALEXANDER GC, Knopman DS, Emerson SS, Ovbiagele B, et al
    Revisiting FDA Approval of Aducanumab.
    N Engl J Med. 2021;385:769-771.
    >> Share

  12. MINTUN MA, Wessels AM, Sims JR
    Donanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2021;385:667.
    >> Share

  13. ESPAY AJ
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021;385:666-667.
    >> Share

    July 2021
  14. RABINOVICI GD
    Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMp2111320.
    >> Share

  15. DUNN B, Stein P, Temple R, Cavazzoni P, et al
    An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMc2111960.
    >> Share

    May 2021
  16. LEVEY AI
    Progress with Treatments for Alzheimer's Disease.
    N Engl J Med. 2021;384:1762-1763.
    >> Share

    March 2021
  17. MINTUN MA, Lo AC, Duggan Evans C, Wessels AM, et al
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021 Mar 13. doi: 10.1056/NEJMoa2100708.
    >> Share

    October 2020
  18. FRIED LP, Rowe JW
    Health in Aging - Past, Present, and Future.
    N Engl J Med. 2020;383:1293-1296.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016